Your browser doesn't support javascript.
loading
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Loibl, Sibylle; de la Pena, Lorena; Nekljudova, Valentina; Zardavas, Dimitrios; Michiels, Stefan; Denkert, Carsten; Rezai, Mahdi; Bermejo, Begoña; Untch, Michael; Lee, Soo Chin; Turri, Sabine; Urban, Patrick; Kümmel, Sherko; Steger, Guenther; Gombos, Andrea; Lux, Michael; Piccart, Martine J; Von Minckwitz, Gunter; Baselga, José; Loi, Sherene.
Afiliação
  • Loibl S; German Breast Group, Neu-Isenburg, Germany; Sana-Klinikum Offenbach, Germany. Electronic address: Sibylle.Loibl@gbg.de.
  • de la Pena L; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Nekljudova V; German Breast Group, Neu-Isenburg, Germany.
  • Zardavas D; Breast International Group, Brussels, Belgium.
  • Michiels S; Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France; CESP, Inserm U1018, Univ. Paris Sud, Univ. Paris-Saclay, Villejuif, France.
  • Denkert C; Institute of Pathology, Charité University Hospital, Berlin, Germany.
  • Rezai M; Luisenkrankenhaus Düsseldorf, Germany.
  • Bermejo B; Hospital Clinico Universitario de Valencia, Spain.
  • Untch M; Helios Klinikum Berlin-Buch, Department of Obstetrics and Gynaecology, Berlin, Germany.
  • Lee SC; Department of Haematology-Oncology, National University Cancer Institute, Singapore.
  • Turri S; Novartis Pharma SAS, Rueil Malmaison, France.
  • Urban P; Novartis Pharma AG, Basel, Switzerland.
  • Kümmel S; Kliniken Essen-Mitte, Essen, Germany.
  • Steger G; Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria; Comprehensive Cancer Center Vienna, Austria.
  • Gombos A; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.
  • Lux M; University Breast Centre of Franconia, OBGYN Department, University Hospital Erlangen, CCC Erlangen-EMN, Germany.
  • Piccart MJ; Breast International Group, Brussels, Belgium; Université Libre de Bruxelles, Institut Jules Rue Héger-Bordet 1, Medical Oncology Clinic, Belgium.
  • Von Minckwitz G; German Breast Group, Neu-Isenburg, Germany.
  • Baselga J; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan-Kettering Cancer Center, New York, USA.
  • Loi S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Australian New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle, Australia. Electronic address: sherene.loi@petermac.org.
Eur J Cancer ; 85: 133-145, 2017 11.
Article em En | MEDLINE | ID: mdl-28923573
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Morfolinas / Paclitaxel / Receptor ErbB-2 / Terapia Neoadjuvante / Inibidores de Proteínas Quinases / Classe I de Fosfatidilinositol 3-Quinases / Trastuzumab Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies País/Região como assunto: Europa / Oceania Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Morfolinas / Paclitaxel / Receptor ErbB-2 / Terapia Neoadjuvante / Inibidores de Proteínas Quinases / Classe I de Fosfatidilinositol 3-Quinases / Trastuzumab Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies País/Região como assunto: Europa / Oceania Idioma: En Ano de publicação: 2017 Tipo de documento: Article